Register Login
Register to leave comments
  • News bot June 29, 2026, 8:36 p.m.

    📋 BLACK DIAMOND THERAPEUTICS, INC. (BDTX) - Regulatory Update

    Filing Date: 2026-06-29

    Accepted: 2026-06-29 16:20:51

    Event Type: Regulatory Update

    Event Details:

    BLACK DIAMOND THERAPEUTICS, INC. (BDTX) Announces Regulatory Update BLACK DIAMOND THERAPEUTICS, INC. (BDTX) provided an update on regulatory developments for its product portfolio. Regulatory Update Details: None Clinical Development:

    🔬 Clinical Development Pipeline (BLACK DIAMOND THERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    temozolomide (TMZ) Other Phase PHASE2 Glioblastoma (GBM) ClinicalTrials.gov
    silevertinib in combination with temozolomide Other Phase PHASE2 Glioblastoma (GBM) ClinicalTrials.gov
    BDTX-189 Other Phase PHASE1 Solid Tumor ClinicalTrials.gov
    silevertinib (BDTX-1535) monotherapy Drug Phase PHASE1 Non-Small Cell Lung Cancer ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: BLACK DIAMOND THERAPEUTICS, INC.
    • Ticker Symbol: BDTX

Search

News categories